(PharmaNewsWire.Com, May 29, 2019 ) The rising demand for synthesized oligos in molecular diagnostics & therapeutics, increasing R&D expenditure by pharmaceutical and biotechnology companies, rising venture capital investments, and the increasing demand for synthetic genes are the major factors driving the growth of this market.
Therapeutic applications segment to grow at the highest CAGR during the forecast period
Based on application, the oligonucleotide synthesis market is segmented into research, diagnostic, and therapeutic applications. The therapeutic applications segment, which is further segmented into RNAi oligonucleotide-based therapies, DNA & antisense oligonucleotide-based therapies, and CpG oligonucleotide-based therapies, is estimated to witness the highest growth during the forecast period. This can primarily be attributed to the investments made by companies to explore the therapeutic applications of oligos.
Also, from 2016 to 2018, more than five oligonucleotide-based therapies were approved by the FDA. In 2018, these oligonucleotide-based drugs generated a revenue of ~USD 2 billion. Apart from this, there are a couple of oligonucleotide-based drugs in Phase III and FDA review, and these drugs might be launched in the next five years and may positively impact this market.
Hospitals accounted for the largest share of the oligonucleotide synthesis market, by end user, in 2018
Based on end user, the oligonucleotide synthesis market is segmented into academic research institutes, diagnostic laboratories, pharmaceutical & biotechnology companies, and hospitals. Hospitals accounted for the largest share of the oligonucleotide synthesis market in 2018. Growth in this end-user segment is largely driven by the significant number of inpatient and outpatient visits in hospitals and the high requirement of oligonucleotide drugs to cater to the demand from the vast patient pool suffering from diseases such as Duchenne muscular dystrophy, spinal muscular atrophy, and hepatic veno-occlusive disease.
North America was the largest regional market for oligonucleotide synthesis in 2018
The oligonucleotide synthesis market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2018, North America accounted for the largest share of the oligonucleotide synthesis market majorly due to the availability of funds for research from various public- and private-sector organizations in the region and the focus of various prominent players on strengthening their presence in North America through product launches and strategic acquisitions and collaborations & agreements. Europe was the second-largest regional market for oligonucleotide synthesis in 2018. This can be attributed to factors such as the presence of a large number of academic and research institutes in the region, growing investments by government bodies and market players, and the increasing focus on R&D activities.
The prominent players operating in the oligonucleotide synthesis market include BioAutomation Corporation (US), LGC Biosearch Technologies (US), Eurogentec (Belgium), GeneDesign, Inc. (Japan), Sarepta Therapeutics (US), Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), GenScript, Inc. (US), Integrated DNA Technologies (IDT, US), Nitto Denko Avecia, Inc. (US), TriLink BioTechnologies (US), Biogen International (US), ATDBio Ltd. (UK), Bio-Synthesis, Inc. (US), Eurofins Genomics (Germany), GE Healthcare (US), Sigma-Aldrich Corporation (a part of Merck KGAA, US), and Sarepta Therapeutics (US).
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
